Skip to main content

Qnami secures investment of 4 million Swiss francs

| News

Qnami secures investment of 4 million Swiss francs


Qnami has raised a total of 4 million Swiss francs from investors after successfully closing a Series A financing round. The Basel Area-based startup has developed a quantum microscope technology that has since been patented as well as producing the first commercial quantum microscope.

The team of Qnami (img: Qnami)

Qnami has announced the successful closing of a Series A financing round in which the startup raised a total of 4 million Swiss francs in fresh capital. Qnami was founded in Basel in 2017 and is now based in Muttenz in the canton of Basel-Landschaft.

The financing round was led by the venture capitalists Runa Capital, which operates out of headquarters in both Silicon Valley and Europe, as well as SIT Capital, which is associated with the Schaffhausen Institute of Technology. The circle of investors included the venture capital companies Quantonation and Verve Ventures, which operate on a pan-European basis, in addition to the Bonn-based High-Tech Gründerfonds and the Cantonal Bank of Zurich.

With this fresh capital injection, Qnami intends to extend its patented quantum microscope technology into applications that will facilitate the design and production of quantum computers and spintronics devices. Furthermore, according to the press release issued by the company, the funds will be used to scale the market launch of the Qnami ProteusQ, the first commercial quantum microscope.

This device uses Qnami’s patented Quantilever diamond scanning probes. “We have gained good market traction with the launch of the ProteusQ and Quantilevers in the materials research setting”, explains Mathieu Munsch, co-founder and CEO of Qnami. “Top researchers already use Qnami’s technology to discover and describe the magnetic properties of new materials”, he adds.

According to Dmitry Galperin, General Partner at Runa Capital, the company is of the view that the technology could also be used for additional applications, including medical imaging and navigation, for example. Galperin is set to join the board of Qnami as a new member.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.